Kyverna Therapeutics has developed a method that enables KYV-101, an experimental CAR T-cell therapy for multiple sclerosis (MS) and other conditions, to be produced in a much shorter timeframe than conventional manufacturing processes, a study shows.
The approach took less than three days to produce KYV-101 from a simple blood draw and the cells were more potent and had more durable activity than the conventionally manufactured product which requires apheresis, a more invasive procedure wherein T-cells are isolated in a machine and grown in a lab until there are millions of them that are then infused back into a patient’s bloodstream….read full article HERE.